The study found an increased risk of hypoglycemia with combination therapy, which decreased with prolonged use. Thiazolidinedione monotherapy was linked to higher mortality compared to GLP-1 RA ...

When a GLP-1 RA is prescribed along with insulin, it can increase the odds of hypoglycemia. Because GLP-1 RAs slow digestion, they may affect how some medications are absorbed. If you have ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation ... outcomes in patients receiving GLP1-RA therapy. There are no published studies ...

GLP-1 RA also significantly reduced the risk of ... (less than 0.1% for both), pancreatic cancer (0.2% for both), severe hypoglycemia (2.5% vs 2.3%), and retinopathy (3.2% for both) — did ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Study: Optimizing Nutrition, Diet, and Lifestyle Communication in GLP-1 Medication ... triggering hypoglycemia, helping reduce appetite and consequently body weight. However, GLP-1 RA therapy ...

The GLP-1 RA and placebo groups had no differences in the risk for serious adverse events, including acute pancreatitis and severe hypoglycemia. "Taken together, these results and the breadth of ...

The researchers found that the incidence of VTE was 11.0 versus 12.9 events per 1,000 patient-years in the GLP-1 RA and DPP-4 inhibitor cohorts, respectively, with an 18 percent lower risk for VTE ...

GLP-1 is an incretin hormone that helps regulate blood glucose levels after meals, acting in a glucose-dependent manner. This means it lowers blood sugar without causing hypoglycemia—a key ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.